奥美沙坦酯对慢性心力衰竭患者心功能、血浆N端脑钠肽前体和血清白细胞介素23水平的影响

发布时间：2018-03-31 14:19

本文选题：奥美沙坦酯　切入点：慢性心力衰竭　出处：《中国药房》2017年29期

【摘要】：目的:探讨奥美沙坦酯对慢性心力衰竭(CHF)患者心功能、血浆N端脑钠肽前体(NT-proBNP)和血清白细胞介素23(IL-23)水平的影响,并对其安全性进行评价。方法:选取2014年12月-2016年5月江苏省涟水县人民医院收治的CHF患者40例作为研究对象,按照随机数字表法分为对照组和观察组,各20例。对照组患者给予马来酸依那普利片起始剂量5 mg,po,qd(1周后逐渐增大剂量,限制剂量为20 mg/d)+酒石酸美托洛尔片25 mg,po,bid+单硝酸异山梨酯片40 mg,po,qd+呋塞米片20 mg,po,bid;观察组患者在对照组基础上加用奥美沙坦酯片20 mg,po,qd。两组患者均连续治疗8周。观察两组患者治疗前后心功能指标[左室舒张末期内径(LVEDD)、左房内径(LAD)、室间隔厚度(IVST)、左室后壁厚度(LVPWT)、左室射血分数(LVEF)、早期充盈E峰速率/晚期充盈A峰速率(E/A)]、血浆NT-proBNP和血清IL-23水平,并记录不良反应发生情况。结果:治疗前,两组患者心功能指标、血浆NT-proBNP和血清IL-23水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者LVEDD、LAD、血浆NTproBNP和血清IL-23水平显著降低,LVEF和E/A水平显著升高,且观察组显著优于对照组,差异均有统计学意义(P0.05)。两组患者IVST和LVPWT水平与治疗前比较,观察组患者的不良反应发生率(25.00%)与对照组(20.00%)比较,差异均无统计学意义(P0.05)。结论:奥美沙坦酯可降低CHF患者血浆NT-proBNP和血清IL-23水平,改善心功能,且安全性较高。
[Abstract]:Methods: 40 CHF patients admitted to Lianshui County people's Hospital of Jiangsu Province from December 2014 to May 2016 were selected as study objects. According to the method of random digital table, they were divided into control group and observation group with 20 cases each.In the control group, the initial dose of enalapril maleate tablets increased gradually after 1 week.The limited dose was 20 mg / d) metoprolol tartrate tablet 25 mg / poprolol bid isosorbide mononitrate tablet 40 mg / L poqd furosemide tablet 20 mg / d furosemide tablet, and the patients in the observation group were treated with omesartan 20 mg / kg poqd.The patients in both groups were treated continuously for 8 weeks.NT-proBNP and serum IL-23 levels,Adverse reactions were recorded.Results: before treatment, there was no significant difference in cardiac function, plasma NT-proBNP and serum IL-23 levels between the two groups (P 0.05).After treatment, the levels of plasma NTproBNP and serum IL-23 in the two groups were significantly lower than those in the control group, and the levels of LVEF and E / A in the observation group were significantly higher than those in the control group (P 0.05).The levels of IVST and LVPWT in the two groups were compared with those before treatment. The incidence of adverse reactions in the observation group was 25.00) and 20.00% in the control group. There was no significant difference between the two groups (P 0.05).Conclusion: omesartan ester can decrease the levels of plasma NT-proBNP and serum IL-23 and improve cardiac function in patients with CHF.
【作者单位】：江苏省涟水县人民医院药剂科;东南大学附属中大医院心内科;江苏省涟水县人民医院心内科;
【分类号】：R541.6

【相似文献】